Dear All,BARDA has released a fascinating Sources Sought Notice (SSN) seeking data on antibacterials near, at, or beyond Phase 2. I've never seen one before, but an SSN is market research with which BARDA will "collect feedback from current and prospective antibiotic development partners" that will "serve as continued market research for potential future acquisitions and programs." While this might sound like just another pipeline review, we'll see in a moment that the query goes well beyond the relatively high-level pipeline reviews maintained by WHO (see the Bugs & Drugs webpage). Here is the link to the SSN along with its title, lightly broken up for ease of reading:SSN No.: BARDA-CBRN-11042024"Antimicrobial Resistance Project BioShield:"BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections"Caused by Drug-Resistant Bacteria or Biothreat Pathogens."The mention in the title of the SSN of "Project BioShield" is our further clue that this is part of BARDA's goal of having at least one MCM for all CBRN threats (translation: one Medical Counter-Measure for all Chemical, Biological, Radiological, and Nuclear threats) as part of their 2022-2026 Strategic Plan. To follow this in more detail, see the 4 Jun 2022 newsletter for more on BARDA's strategic plan and the 12 Nov...